Profile: Sorrento Therapeutics Inc (SRNE.OQ)
Sorrento Therapeutics, Inc., incorporated on December 4, 2009, is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs for solid tumors, resiniferatoxin (RTX), a non-opiate, ultra-potent and selective agonist of the transient receptor potential cation channel subfamily V member 1 (TRPV-1) receptor for intractable pain in end-stage disease, and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy.
RTX is a small molecule with a non-opiate mechanism of action that may permanently eliminate intractable cancer pain experienced by end-stage cancer patients. When injected intraspinally or paraspinally, RTX directly interacts with nerve cells expressing TRPV-1 receptors without affecting normal sensation, such as touch and vibration sense or muscle function. The Company has conducted an investigator-sponsored Phase I/II clinical trial at the National Institute of Health (NIH). The Company is testing targeted injections into or near specific ganglia. The Company is also evaluating other severe pain indications.
The Company's G-MAB library is a fully human antibody library. The Company's preclinical mAb related to its anti-programmed cell death protein 1 (PD-1) antibody is STI-A1110. The Company's preclinical mAbs related to anti-programmed cell death 1 ligand 1 (PD-L1) antibodies are STI-A1014 (lead candidate), and STI-A1015. The Company's anti-vascular endothelial growth factor receptor 2 (VEGFR2) mAb includes STI-A0168.
Antibody Drug Conjugates (ADC) Technologies
The Company's ADCs have cytotoxic payloads, as well as C-Lock and K-Lock conjugation technologies that allow for site-specific toxin conjugation to the antibody. The ADC technology helps in its existing development programs, particularly its G-MAB-derived monoclonal antibodies. Its ADC projects utilize G-MAB-derived c-MET and c-MET/EGFR antibodies.
The Company competes with BMS, Merck, Genentech, AstraZeneca and Serono/Pfizer.
Sorrento Therapeutics Inc
4955 Directors Pl
SAN DIEGO CA 92121-3836